SOSV

Ria Health is an online platform that provides telehealth services aimed at helping individuals modify their relationship with alcohol. It offers personalized treatment plans that include medication-assisted options and behavioral therapies, all facilitated by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability. Ria Health also features a mobile app that provides access to educational materials, support groups, and communication with care teams. This comprehensive approach is designed to assist users in managing alcohol consumption and fostering healthier habits, ultimately addressing the challenges associated with alcohol use disorder.

Oxyle specializes in wastewater treatment, focusing on the removal of hazardous micropollutants such as pesticides, chemicals, pharmaceuticals, and endocrine disruptors. Serving industries like pharmaceuticals, biotech, chemicals, food & beverage, electronics, hospitals, and wastewater plants, Oxyle's innovative technology helps reduce toxic pollutants and carbon emissions while providing regulatory relief to clients.

Particella is a biotechnology company that specializes in developing a proprietary oral lipid nanoparticle technology designed to deliver mRNA and other nucleic acids. This innovative approach aims to transform the administration of biological medicines by utilizing the intestinal tract to facilitate the secretion of proteins into the bloodstream. By enabling the oral delivery of protein biologics, Particella's technology seeks to address the limitations of current methods, ultimately allowing healthcare providers to prevent gastrointestinal diseases in patients more effectively. The company's advancements hold the potential to create a new category of medicines, enhancing the accessibility and efficacy of treatments.

RyboDyn is a biotechnology research company focused on developing innovative therapeutics aimed at training the immune system to identify and eliminate cancer from within the body. By leveraging cutting-edge scientific breakthroughs, RyboDyn creates advanced treatments that promise significant improvements in the management of terminal diseases and various ailments. The company's commitment to enhancing medicine through its research positions it at the forefront of the fight against cancer, with the potential to transform patient care and outcomes.

Ten63 Therapeutics, Inc. is a biotechnology company based in Chapel Hill, North Carolina, focused on developing potent therapeutics for medically validated yet undruggable targets. Founded in 2017, the company utilizes its innovative platform, COPPER, which combines machine learning-based computational chemistry with advanced physical modeling to explore an extensive chemical space. This approach allows Ten63 Therapeutics to discover novel drug candidates for some of the most lethal diseases by employing proprietary algorithms for scaffold redesign and optimizing chemical design. By integrating these technologies, the company aims to produce durable therapies and improve drug resistance prediction, ultimately addressing challenges in drug development for previously intractable targets.

BioSapien is a biotechnology company developing innovative, biodegradable implantable devices that deliver pharmaceuticals directly to cancer sites. Its flagship product, MediChip, uses 3D printing technology to create a mesh capable of sustained drug release, reducing systemic side effects and improving patient care.

Vitarka Therapeutics is a London-based company that specializes in developing medical technologies and solutions aimed at treating various types of cancer. The company has created a targeted non-viral delivery platform designed for intracellular targets, particularly in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage cancer patients, including those with lung, colon, and breast cancers. By utilizing re-engineered pore-forming proteins, Vitarka Therapeutics enables cell-specific targeting and endosomal release of therapeutic cargo, providing cancer patients with improved prospects for leading normal lives and maintaining hope for the future.

VIAN Therapeutics is an early-stage biotechnology company focused on transforming retinal disease treatment. Its lead product, a first-in-class non-invasive eyedrop, aims to replace invasive injections for conditions like age-related macular degeneration and diabetic macular edema.

Capra Biosciences is a biotechnology company that develops bioreactor technology to enable efficient, low-carbon production of bio-based chemicals. Its biofilm bioreactor platform reduces downstream processing requirements and costs in bio-manufacturing and supports the production of hydrophobic products, including fuels, retinol, and performance lubricants.

Founded in 2022 and headquartered in Berkeley, California, Laguna Bio develops a drug discovery platform designed to selectively activate and expand the innate immune system against cancer. The company focuses on providing a specific type of T cell for the immune system to fight solid tumors by increasing the response rate of bispecific antibody drugs.

FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

DNAzyme is a biotechnology company specializing in the development of enzymes derived from Antarctic extremophile microorganisms as active ingredients for skin health applications. Utilizing recombinant DNA repair technology, the company produces highly pure enzymes at an industrial scale, enabling clinicians to create innovative solutions for skin health and rejuvenation in both the cosmetic and pharmaceutical industries.

VALANX Biotech GmbH is an innovative biotechnology company based in Klosterneuburg, Austria, founded in 2017. The company specializes in the development and manufacturing of synthetic programmable amino acids, notably Norl, and the reactive amino acid SnapIt. These products are designed to facilitate the creation of antibody-drug conjugates, which enhance cancer treatment by selectively targeting cancer cells. VALANX Biotech’s platform also supports PEGylation of therapeutic peptides and proteins, as well as the directed and oriented immobilization of biosensors and biocatalysts. Additionally, the company offers bioanalytics and mass spectrometry services on demand, helping to streamline the development of site-specific protein-drug conjugates in a cost-effective manner.

VIAN Therapeutics is an early-stage biotechnology company focused on transforming retinal disease treatment. Its lead product, a first-in-class non-invasive eyedrop, aims to replace invasive injections for conditions like age-related macular degeneration and diabetic macular edema.

Founded in 2020, Prolific Machines is a San Francisco-based biotech company dedicated to revolutionizing cell production for a sustainable future. It combines advanced technologies to enable large-scale cell manufacturing, aiming to improve therapeutic protein production for biotechnology and pharmaceutical companies.

VisusNano Ltd. is a London-based company founded in 2016 that specializes in the development of a drug-eluting intraocular lens implant designed for use in cataract surgery. This innovative technology aims to enhance patient outcomes by reducing the risks associated with the procedure, such as intraocular inflammation, infection, and opacification. By eliminating the need for postoperative eye drops and minimizing the necessity for laser treatments, VisusNano's product has the potential to transform cataract surgery for both human and veterinary patients. The company is currently in the pre-clinical stage of its development.

Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.

Calder Biosciences engineers next-generation vaccines using its proprietary 3D-Vaxlock technology. This platform generates molecular staples that lock vaccines into their most potent shape, enhancing immune response and stability. Calder's initial focus is on developing a universal flu vaccine and an RSV vaccine for the elderly. Their vaccines aim to protect against life-threatening diseases with improved safety, efficacy, and durability, reducing healthcare burden globally.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

Reactosome is a biotechnology company that develops synthetic nuclei for gene therapy. Its core product, a synthetic nucleus, operates continuously within cells, mimicking the natural nucleus to affect multiple genes simultaneously. This approach aims to enhance the safety and longevity of gene expression, thereby enabling the development of treatments for complex diseases such as cancer and age-related disorders.

RyboDyn is a biotechnology research company focused on developing innovative therapeutics aimed at training the immune system to identify and eliminate cancer from within the body. By leveraging cutting-edge scientific breakthroughs, RyboDyn creates advanced treatments that promise significant improvements in the management of terminal diseases and various ailments. The company's commitment to enhancing medicine through its research positions it at the forefront of the fight against cancer, with the potential to transform patient care and outcomes.

VALANX Biotech GmbH is an innovative biotechnology company based in Klosterneuburg, Austria, founded in 2017. The company specializes in the development and manufacturing of synthetic programmable amino acids, notably Norl, and the reactive amino acid SnapIt. These products are designed to facilitate the creation of antibody-drug conjugates, which enhance cancer treatment by selectively targeting cancer cells. VALANX Biotech’s platform also supports PEGylation of therapeutic peptides and proteins, as well as the directed and oriented immobilization of biosensors and biocatalysts. Additionally, the company offers bioanalytics and mass spectrometry services on demand, helping to streamline the development of site-specific protein-drug conjugates in a cost-effective manner.

FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

Calder Biosciences engineers next-generation vaccines using its proprietary 3D-Vaxlock technology. This platform generates molecular staples that lock vaccines into their most potent shape, enhancing immune response and stability. Calder's initial focus is on developing a universal flu vaccine and an RSV vaccine for the elderly. Their vaccines aim to protect against life-threatening diseases with improved safety, efficacy, and durability, reducing healthcare burden globally.

BryoSphere is a company specializing in the manufacturing of specialty chemicals, employing moss plants and biotechnology methods in the production of their goods. The company is currently focused on the development of two key products: one for addressing skin hyperpigmentation in topical treatments, and another as an anti-cancer drug.

BioSapien is a biotechnology company developing innovative, biodegradable implantable devices that deliver pharmaceuticals directly to cancer sites. Its flagship product, MediChip, uses 3D printing technology to create a mesh capable of sustained drug release, reducing systemic side effects and improving patient care.

VALANX Biotech GmbH is an innovative biotechnology company based in Klosterneuburg, Austria, founded in 2017. The company specializes in the development and manufacturing of synthetic programmable amino acids, notably Norl, and the reactive amino acid SnapIt. These products are designed to facilitate the creation of antibody-drug conjugates, which enhance cancer treatment by selectively targeting cancer cells. VALANX Biotech’s platform also supports PEGylation of therapeutic peptides and proteins, as well as the directed and oriented immobilization of biosensors and biocatalysts. Additionally, the company offers bioanalytics and mass spectrometry services on demand, helping to streamline the development of site-specific protein-drug conjugates in a cost-effective manner.

Artyc specializes in providing sustainable cold shipping solutions tailored for the biotech, pharmaceutical, and medical sectors. The company manufactures refrigerant-free, reusable, active cooling containers that enhance the efficiency of cold logistics. By focusing on decarbonizing the cold chain, Artyc aims to create a more sustainable logistics industry. Their innovative containers not only help businesses reduce shipping costs but also enable effective temperature monitoring, ensuring the safe transport of sensitive goods.

VIAN Therapeutics is an early-stage biotechnology company focused on transforming retinal disease treatment. Its lead product, a first-in-class non-invasive eyedrop, aims to replace invasive injections for conditions like age-related macular degeneration and diabetic macular edema.

Pannex Therapeutics is a New York-based biopharmaceutical company focused on developing innovative cancer therapies. It specializes in Pannexin 1 channel blockers, a novel class of drugs designed to inhibit multiple pathways, preventing cancer cell growth, metastasis, and survival.

Pear Bio is a biotechnology company based in Boston and London. It develops precision medicine-guided therapeutics for hard-to-treat cancers using AI. The company analyzes tumor biopsies and blood to identify new targets, then tests drug candidates directly on patient samples using its proprietary immune-microtumor system.

Ten63 Therapeutics, Inc. is a biotechnology company based in Chapel Hill, North Carolina, focused on developing potent therapeutics for medically validated yet undruggable targets. Founded in 2017, the company utilizes its innovative platform, COPPER, which combines machine learning-based computational chemistry with advanced physical modeling to explore an extensive chemical space. This approach allows Ten63 Therapeutics to discover novel drug candidates for some of the most lethal diseases by employing proprietary algorithms for scaffold redesign and optimizing chemical design. By integrating these technologies, the company aims to produce durable therapies and improve drug resistance prediction, ultimately addressing challenges in drug development for previously intractable targets.

Vitarka Therapeutics is a London-based company that specializes in developing medical technologies and solutions aimed at treating various types of cancer. The company has created a targeted non-viral delivery platform designed for intracellular targets, particularly in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage cancer patients, including those with lung, colon, and breast cancers. By utilizing re-engineered pore-forming proteins, Vitarka Therapeutics enables cell-specific targeting and endosomal release of therapeutic cargo, providing cancer patients with improved prospects for leading normal lives and maintaining hope for the future.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

Particella is a biotechnology company that specializes in developing a proprietary oral lipid nanoparticle technology designed to deliver mRNA and other nucleic acids. This innovative approach aims to transform the administration of biological medicines by utilizing the intestinal tract to facilitate the secretion of proteins into the bloodstream. By enabling the oral delivery of protein biologics, Particella's technology seeks to address the limitations of current methods, ultimately allowing healthcare providers to prevent gastrointestinal diseases in patients more effectively. The company's advancements hold the potential to create a new category of medicines, enhancing the accessibility and efficacy of treatments.

Kolibri specializes in developing innovative bioreactors that significantly enhance cell culture yields while reducing production costs. Their proprietary platform, combining cutting-edge acoustics and biology techniques, aims to make cell and gene therapies more accessible and affordable.

FluoSphera is a biotechnology company focused on developing safer and more effective drugs. It aims to minimize adverse side effects and reduce reliance on animal testing by leveraging innovative drug discovery technologies. This enables FluoSphera's partners to better understand human physiological responses and safeguard populations from harmful chemicals more efficiently.

Pear Bio is a biotechnology company based in Boston and London. It develops precision medicine-guided therapeutics for hard-to-treat cancers using AI. The company analyzes tumor biopsies and blood to identify new targets, then tests drug candidates directly on patient samples using its proprietary immune-microtumor system.

VisusNano Ltd. is a London-based company founded in 2016 that specializes in the development of a drug-eluting intraocular lens implant designed for use in cataract surgery. This innovative technology aims to enhance patient outcomes by reducing the risks associated with the procedure, such as intraocular inflammation, infection, and opacification. By eliminating the need for postoperative eye drops and minimizing the necessity for laser treatments, VisusNano's product has the potential to transform cataract surgery for both human and veterinary patients. The company is currently in the pre-clinical stage of its development.

Oxyle specializes in wastewater treatment, focusing on the removal of hazardous micropollutants such as pesticides, chemicals, pharmaceuticals, and endocrine disruptors. Serving industries like pharmaceuticals, biotech, chemicals, food & beverage, electronics, hospitals, and wastewater plants, Oxyle's innovative technology helps reduce toxic pollutants and carbon emissions while providing regulatory relief to clients.

Founded in 2020, Prolific Machines is a San Francisco-based biotech company dedicated to revolutionizing cell production for a sustainable future. It combines advanced technologies to enable large-scale cell manufacturing, aiming to improve therapeutic protein production for biotechnology and pharmaceutical companies.

FluoSphera is a biotechnology company focused on developing safer and more effective drugs. It aims to minimize adverse side effects and reduce reliance on animal testing by leveraging innovative drug discovery technologies. This enables FluoSphera's partners to better understand human physiological responses and safeguard populations from harmful chemicals more efficiently.

BioSapien is a biotechnology company developing innovative, biodegradable implantable devices that deliver pharmaceuticals directly to cancer sites. Its flagship product, MediChip, uses 3D printing technology to create a mesh capable of sustained drug release, reducing systemic side effects and improving patient care.

Vitarka Therapeutics is a London-based company that specializes in developing medical technologies and solutions aimed at treating various types of cancer. The company has created a targeted non-viral delivery platform designed for intracellular targets, particularly in oncology, neuroscience, and neurodegeneration. This innovative platform works by activating the immune system and normalizing tumor vasculature, significantly improving outcomes for late-stage cancer patients, including those with lung, colon, and breast cancers. By utilizing re-engineered pore-forming proteins, Vitarka Therapeutics enables cell-specific targeting and endosomal release of therapeutic cargo, providing cancer patients with improved prospects for leading normal lives and maintaining hope for the future.

Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.

Spindle Biotech Inc., founded in 2017 and headquartered in Toronto, Canada, specializes in the development and commercialization of synthetic RNA technologies. The company focuses on a proprietary RNA polymerase that enhances large-scale mRNA vaccine production, reflecting the increasing relevance of synthetic RNA in biotechnological applications. Leveraging advances in mRNA technology, Spindle Biotech aims to facilitate high-throughput ribonucleoprotein (RNP)-based CRISPR and RNA screening. Utilizing advanced enzymes and microfluidic technology, it creates RNA arrays with high fidelity, which are vital for gene-editing and drug discovery initiatives. Through these innovations, Spindle Biotech seeks to support biotechnology companies in harnessing the transformative potential of synthetic RNA.

Intrinsic Medicine, Inc. is a clinical-stage company based in Des Moines, Washington, focused on researching and developing innovative medicines for patients. Formerly known as Lupa Bio, the company specializes in the development of prebiotic drugs aimed at treating various human diseases. Its flagship products, Human Identical Milk Oligosaccharides (HiMOs), are engineered to remain stable in stomach acid and resist degradation in the upper gastrointestinal tract. This unique formulation allows patients to enhance gut health and modulate immune responses effectively. As a venture-backed entity, Intrinsic Medicine operates with a technical and operational platform designed to bring significant medical advancements to patients in an efficient and ethical manner.

Founded in 2022 and headquartered in Berkeley, California, Laguna Bio develops a drug discovery platform designed to selectively activate and expand the innate immune system against cancer. The company focuses on providing a specific type of T cell for the immune system to fight solid tumors by increasing the response rate of bispecific antibody drugs.

Dandelion is a therapeutic company that focuses on training AI models that can design organ and cell-type-specific drug delivery vehicles. Dandelion was founded in 2022.

Prospective Research, Inc., based in Beverly, Massachusetts, specializes in developing innovative solutions for antibiotic discovery and disease management in aquaculture. Founded in 2015, the company utilizes its proprietary MicrobeMiner platform to access untapped antibiotics by mimicking natural soil stimuli. Its GeneMiner technology aligns specific microbes with targeted stimuli, while the StimKeys technology reproduces these stimuli to unlock microbial natural products. Additionally, Prospective Research is pioneering feed-integrated preventative disease management solutions that eliminate the need for traditional antibiotics in aquaculture. By employing microbial signaling molecules, the company can modulate bacterial behavior and deliver therapeutics directly to the gut of farmed species. Prospective Research introduces trillions of beneficial bacteria into the microbiome of fin-fish, shrimp, and shellfish, enabling selective activation of bacterial genes that produce bio-active therapeutics to combat various pathogens.

Chronos DX is a biotechnology research company based in London, Germany, specializing in drug development and in vitro diagnostics within the healthcare sector. The company is known for its innovative bioassay technology, which is designed for diagnostics, drug screening, and development. Chronos DX focuses on creating high-performance, low-cost, and scalable technology capable of detecting a variety of biomarkers, including cell-free DNA, micro proteins, exosomes, and metabolites. This technology provides medical professionals with a platform for in-line and in vivo monitoring of biomarkers, enhancing the capabilities of diagnostics and drug development in medical practice.

SyntheX specializes in drug discovery using synthetic biology platforms. It identifies protein interaction modulators and enables functional protein degradation, focusing on unique mechanisms for cancer and rare disease treatments.

Ria Health is an online platform that provides telehealth services aimed at helping individuals modify their relationship with alcohol. It offers personalized treatment plans that include medication-assisted options and behavioral therapies, all facilitated by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability. Ria Health also features a mobile app that provides access to educational materials, support groups, and communication with care teams. This comprehensive approach is designed to assist users in managing alcohol consumption and fostering healthier habits, ultimately addressing the challenges associated with alcohol use disorder.

Pannex Therapeutics is a New York-based biopharmaceutical company focused on developing innovative cancer therapies. It specializes in Pannexin 1 channel blockers, a novel class of drugs designed to inhibit multiple pathways, preventing cancer cell growth, metastasis, and survival.

Pregenerate, Inc., founded in 2019 and incorporated in Delaware, specializes in developing innovative organ-on-a-chip technology aimed at replacing animal testing in medical and pharmaceutical research, particularly for arthritis treatments. The company's scalable models utilize human cells, allowing pharmaceutical companies to significantly reduce costs and improve drug success rates. Pregenerate's technology not only enhances the efficiency of research but also facilitates the stratification of patients into targeted treatment subgroups, enabling personalized medicine approaches. By providing these advanced solutions, Pregenerate aims to transform the research landscape and improve treatment outcomes for individuals with arthritis.

Capra Biosciences is a biotechnology company that develops bioreactor technology to enable efficient, low-carbon production of bio-based chemicals. Its biofilm bioreactor platform reduces downstream processing requirements and costs in bio-manufacturing and supports the production of hydrophobic products, including fuels, retinol, and performance lubricants.

Alternative Plants, SIA is a biotech start-up based in Riga, Latvia, founded in 2017, specializing in the development of active ingredients derived from plant stem cell cultures. The company focuses on creating sustainable and effective cosmetic ingredients, particularly for the anti-aging and skin whitening markets. By utilizing stem cell technology, Alternative Plants aims to produce valuable substances from rare and difficult-to-cultivate medicinal plants, ensuring a consistent and sustainable supply of these ingredients. Their primary clients are cosmetic manufacturers who incorporate these plant stem cell-derived active substances into their products. The company also envisions future expansion into other sectors, including functional foods, medical devices, and pharmaceuticals, leveraging their innovative technology to broaden their impact.

Artyc specializes in providing sustainable cold shipping solutions tailored for the biotech, pharmaceutical, and medical sectors. The company manufactures refrigerant-free, reusable, active cooling containers that enhance the efficiency of cold logistics. By focusing on decarbonizing the cold chain, Artyc aims to create a more sustainable logistics industry. Their innovative containers not only help businesses reduce shipping costs but also enable effective temperature monitoring, ensuring the safe transport of sensitive goods.

Artyc specializes in providing sustainable cold shipping solutions tailored for the biotech, pharmaceutical, and medical sectors. The company manufactures refrigerant-free, reusable, active cooling containers that enhance the efficiency of cold logistics. By focusing on decarbonizing the cold chain, Artyc aims to create a more sustainable logistics industry. Their innovative containers not only help businesses reduce shipping costs but also enable effective temperature monitoring, ensuring the safe transport of sensitive goods.

Founded in August 2019, Portable Diagnostic Systems develops a microfluidics-based drug testing platform for law enforcement. This platform uses salivary diagnostics, antibody engineering, and micro-fluidics to accurately screen drugs from a small saliva sample collected at roadside stops, aiming to reduce false positives and enhance traffic stop efficiency.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

Proteinea develops a protein engineering platform that uses proprietary AI models and computational tools to design next-generation antibodies with enhanced efficacy, safety, and convenience. The company aims to make biotherapeutics development smarter, safer, and faster.

Cayuga Biotech is a biotechnology company developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. Its polyphosphate-based drug accelerates the body's natural clotting process to contain bleeding at the injury site, minimizing potential side effects. Cayuga focuses on treating traumatic hemorrhage and rare bleeding disorders.

Inso Biosciences is an early-stage biotechnology company that develops microfluidic hardware platforms for genomic sample handling. The company's patented microfluidic technology enables high-efficiency processing of cellular material and the separation and isolation of cellular components, supporting genomic analysis and DNA sequencing workflows. Its platform aims to improve long-read DNA extraction, multiomic sample processing, and pathogen surveillance, enabling healthcare and biotech organizations to perform biological sample preparation with greater efficiency and accuracy.

Capra Biosciences is a biotechnology company that develops bioreactor technology to enable efficient, low-carbon production of bio-based chemicals. Its biofilm bioreactor platform reduces downstream processing requirements and costs in bio-manufacturing and supports the production of hydrophobic products, including fuels, retinol, and performance lubricants.

VALANX Biotech GmbH is an innovative biotechnology company based in Klosterneuburg, Austria, founded in 2017. The company specializes in the development and manufacturing of synthetic programmable amino acids, notably Norl, and the reactive amino acid SnapIt. These products are designed to facilitate the creation of antibody-drug conjugates, which enhance cancer treatment by selectively targeting cancer cells. VALANX Biotech’s platform also supports PEGylation of therapeutic peptides and proteins, as well as the directed and oriented immobilization of biosensors and biocatalysts. Additionally, the company offers bioanalytics and mass spectrometry services on demand, helping to streamline the development of site-specific protein-drug conjugates in a cost-effective manner.

Circularis Biotechnologies, Inc. is a biotechnology company founded in 2014 and headquartered in Oakland, California. The company specializes in developing innovative methods to regulate gene expression, which enhances the production yields of biotherapeutics. Circularis offers a range of products, including RACRE Variant Libraries, hCMV Variant Library, Protein expression with CMV promoters, and T7 Variant Library. In addition, it provides various services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. Through its advanced technologies and services, Circularis aims to improve the efficiency and effectiveness of biotherapeutic production.

Founded in 2020, Prolific Machines is a San Francisco-based biotech company dedicated to revolutionizing cell production for a sustainable future. It combines advanced technologies to enable large-scale cell manufacturing, aiming to improve therapeutic protein production for biotechnology and pharmaceutical companies.

Ardra Inc. is a renewable chemicals company based in Toronto, Canada, specializing in the production of petroleum-free specialty chemicals for the personal care and cosmetics industry. Utilizing technology developed at the University of Toronto, Ardra employs model-guided metabolic engineering and synthetic biology to create biocatalysts that convert renewable resources into essential chemicals. The company's flagship product is 1,3-butanediol, a sustainable alternative to petroleum-based counterparts, which is utilized in various applications including cosmetics, food, polymers, and pharmaceuticals. With the cosmetics sector relying heavily on petroleum chemicals, valued at approximately $2.6 billion, Ardra aims to provide environmentally friendly solutions that stabilize and sustain the supply chain while reducing ecological impact.

BioSapien is a biotechnology company developing innovative, biodegradable implantable devices that deliver pharmaceuticals directly to cancer sites. Its flagship product, MediChip, uses 3D printing technology to create a mesh capable of sustained drug release, reducing systemic side effects and improving patient care.

Prothegen is a biotechnology company located in Palo Alto, California, focused on developing innovative medicines that precisely regulate cell death. The company has created a platform aimed at delivering therapies that can either inhibit or promote ferroptosis, a form of regulated cell death. By targeting this mechanism, Prothegen seeks to provide effective therapeutics that can prevent unwanted cell death, thereby improving treatment options for various diseases.

Prothegen is a biotechnology company located in Palo Alto, California, focused on developing innovative medicines that precisely regulate cell death. The company has created a platform aimed at delivering therapies that can either inhibit or promote ferroptosis, a form of regulated cell death. By targeting this mechanism, Prothegen seeks to provide effective therapeutics that can prevent unwanted cell death, thereby improving treatment options for various diseases.

Pannex Therapeutics is a New York-based biopharmaceutical company focused on developing innovative cancer therapies. It specializes in Pannexin 1 channel blockers, a novel class of drugs designed to inhibit multiple pathways, preventing cancer cell growth, metastasis, and survival.

Pannex Therapeutics is a New York-based biopharmaceutical company focused on developing innovative cancer therapies. It specializes in Pannexin 1 channel blockers, a novel class of drugs designed to inhibit multiple pathways, preventing cancer cell growth, metastasis, and survival.

Indee Labs develops hardware and platform technologies for gene delivery to immune cells, with the aim of enabling the rapid development and scalable manufacture of gene-modified cell therapies, including CAR-T cells. The company focuses on non-viral delivery methods to introduce small molecules, nucleic acids, proteins, and gene-editing complexes into immune cells, supporting biopharmaceutical research and manufacturing while maintaining high cell viability and function. Its technology has progressed with collaboration from national facilities and through participation in biotech incubators and accelerators. Indee Labs maintains an international footprint, with an office in Sydney and lab space in Berkeley, reflecting its cross-regional development and manufacturing focus.

Pear Bio is a biotechnology company based in Boston and London. It develops precision medicine-guided therapeutics for hard-to-treat cancers using AI. The company analyzes tumor biopsies and blood to identify new targets, then tests drug candidates directly on patient samples using its proprietary immune-microtumor system.

Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.

Helex is a biotechnology company developing genomic medicines for kidney-related diseases. It leverages its own genomics data, bioinformatics, and an intelligent data-driven platform to design, verify, and deliver therapy-specific gRNAs, with a focus on non-viral targeted delivery and genome editing for renal indications. The company's platform uses data-driven deep-learning models and high-throughput sequencing data from CRISPR edits in human cell lines to generate reliable predictions and validate them in-house. By combining these capabilities, Helex aims to accelerate CRISPR-based drug research and the development of cell and gene therapies for kidney conditions, offering precise and scalable renal therapeutics.

RxAll, Inc. is a technology company that specializes in developing an artificial intelligence-driven platform for the authentication and distribution of pharmaceuticals, primarily in Africa. Founded in 2015 and headquartered in New Haven, Connecticut, the company utilizes a deep learning hyperspectral Internet of Things (IoT) platform that incorporates a molecular sensor device and a cloud database of spectral signatures. This innovative approach allows for non-destructive authentication of medications, including prescription and over-the-counter drugs, before they are dispensed. RxAll aims to combat the issue of counterfeit drugs by providing real-time information to pharmaceutical manufacturers about the authenticity of their products. Additionally, the platform facilitates access to authenticated medicines for patients and pharmacies, while also offering tele-pharmacy primary care services.

Microbiome-focused therapeutics for diseases of the oral cavity and their systemic effects

Intrinsic Medicine, Inc. is a clinical-stage company based in Des Moines, Washington, focused on researching and developing innovative medicines for patients. Formerly known as Lupa Bio, the company specializes in the development of prebiotic drugs aimed at treating various human diseases. Its flagship products, Human Identical Milk Oligosaccharides (HiMOs), are engineered to remain stable in stomach acid and resist degradation in the upper gastrointestinal tract. This unique formulation allows patients to enhance gut health and modulate immune responses effectively. As a venture-backed entity, Intrinsic Medicine operates with a technical and operational platform designed to bring significant medical advancements to patients in an efficient and ethical manner.

CyGenica develops non-viral, non-toxic platforms for delivering drugs, gene editing components, and antibiotics into cells. Its technology enables targeted delivery to specific cellular locations, enhancing the efficacy of pharmaceuticals.

Capra Biosciences is a biotechnology company that develops bioreactor technology to enable efficient, low-carbon production of bio-based chemicals. Its biofilm bioreactor platform reduces downstream processing requirements and costs in bio-manufacturing and supports the production of hydrophobic products, including fuels, retinol, and performance lubricants.

Pregenerate, Inc., founded in 2019 and incorporated in Delaware, specializes in developing innovative organ-on-a-chip technology aimed at replacing animal testing in medical and pharmaceutical research, particularly for arthritis treatments. The company's scalable models utilize human cells, allowing pharmaceutical companies to significantly reduce costs and improve drug success rates. Pregenerate's technology not only enhances the efficiency of research but also facilitates the stratification of patients into targeted treatment subgroups, enabling personalized medicine approaches. By providing these advanced solutions, Pregenerate aims to transform the research landscape and improve treatment outcomes for individuals with arthritis.

Ria Health is an online platform that provides telehealth services aimed at helping individuals modify their relationship with alcohol. It offers personalized treatment plans that include medication-assisted options and behavioral therapies, all facilitated by licensed healthcare professionals. The platform emphasizes continuous monitoring to help users track their progress and maintain accountability. Ria Health also features a mobile app that provides access to educational materials, support groups, and communication with care teams. This comprehensive approach is designed to assist users in managing alcohol consumption and fostering healthier habits, ultimately addressing the challenges associated with alcohol use disorder.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative gene therapy treatments for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, the company utilizes advanced oral lipid nanoparticle technology to deliver mRNA and plasmid DNA directly to intestinal stem cells. This approach aims to address the root causes of gastrointestinal diseases, including Familial Adenomatous Polyposis (FAP), a hereditary condition that can lead to colorectal cancer and often necessitates invasive surgical interventions. DNALite's therapies seek to transform protein biologics into oral drugs, allowing for more effective and less invasive treatment options.

Kolibri specializes in developing innovative bioreactors that significantly enhance cell culture yields while reducing production costs. Their proprietary platform, combining cutting-edge acoustics and biology techniques, aims to make cell and gene therapies more accessible and affordable.

Founded in 2020, Prolific Machines is a San Francisco-based biotech company dedicated to revolutionizing cell production for a sustainable future. It combines advanced technologies to enable large-scale cell manufacturing, aiming to improve therapeutic protein production for biotechnology and pharmaceutical companies.

Wayfinder Biosciences is a biotechnology company focused on developing orally available small molecule drugs that modulate RNA targets linked to cancer and neurodegenerative diseases. The company uses a proprietary platform that combines high-throughput screening, computational modeling, and machine learning with unique datasets to discover RNA-targeting compounds with potency and selectivity for traditionally inaccessible targets. Its approach includes RNA biosensor technologies that render target molecules detectable, aiding discovery and evaluation. Founded in 2021 and based in Seattle, Wayfinder aims to accelerate development of therapies for undruggable targets by enabling rapid screening and optimization of RNA-targeting small molecules.

Proteinea develops a protein engineering platform that uses proprietary AI models and computational tools to design next-generation antibodies with enhanced efficacy, safety, and convenience. The company aims to make biotherapeutics development smarter, safer, and faster.

Ten63 Therapeutics, Inc. is a biotechnology company based in Chapel Hill, North Carolina, focused on developing potent therapeutics for medically validated yet undruggable targets. Founded in 2017, the company utilizes its innovative platform, COPPER, which combines machine learning-based computational chemistry with advanced physical modeling to explore an extensive chemical space. This approach allows Ten63 Therapeutics to discover novel drug candidates for some of the most lethal diseases by employing proprietary algorithms for scaffold redesign and optimizing chemical design. By integrating these technologies, the company aims to produce durable therapies and improve drug resistance prediction, ultimately addressing challenges in drug development for previously intractable targets.

Pear Bio is a biotechnology company based in Boston and London. It develops precision medicine-guided therapeutics for hard-to-treat cancers using AI. The company analyzes tumor biopsies and blood to identify new targets, then tests drug candidates directly on patient samples using its proprietary immune-microtumor system.

Biomage is a company dedicated to advancing life sciences through innovative single-cell analysis. It offers a platform that enables researchers to analyze vast single-cell sequencing data efficiently, transforming complex biological data into actionable insights. This capability supports both academic and industrial scientists in enhancing drug target discovery while reducing costs. The Biomage Single Cell Platform allows users to manage their single-cell data analysis with ease, providing deep biological insights in a streamlined manner. By applying advanced computational methods, Biomage is at the forefront of facilitating groundbreaking research across various biological disciplines.

Microbiome-focused therapeutics for diseases of the oral cavity and their systemic effects

Capra Biosciences is a biotechnology company that develops bioreactor technology to enable efficient, low-carbon production of bio-based chemicals. Its biofilm bioreactor platform reduces downstream processing requirements and costs in bio-manufacturing and supports the production of hydrophobic products, including fuels, retinol, and performance lubricants.

RxAll, Inc. is a technology company that specializes in developing an artificial intelligence-driven platform for the authentication and distribution of pharmaceuticals, primarily in Africa. Founded in 2015 and headquartered in New Haven, Connecticut, the company utilizes a deep learning hyperspectral Internet of Things (IoT) platform that incorporates a molecular sensor device and a cloud database of spectral signatures. This innovative approach allows for non-destructive authentication of medications, including prescription and over-the-counter drugs, before they are dispensed. RxAll aims to combat the issue of counterfeit drugs by providing real-time information to pharmaceutical manufacturers about the authenticity of their products. Additionally, the platform facilitates access to authenticated medicines for patients and pharmacies, while also offering tele-pharmacy primary care services.

AsimicA, founded by Nikolai Mushnikov and Grant Bowman in November 2018, specializes in developing innovative technologies aimed at enhancing production efficiency in microbial biosynthetic factories. The company's core focus is on improving yields of biosynthetic processes, a significant challenge in biotechnology due to relatively low product outputs. AsimicA's novel approaches, centered around microbial stem cell technology, have the potential to revolutionize the industry by enabling multi-fold increases in production efficiency, particularly for pharmaceutical biomolecules.

Cayuga develops novel hemostatic drugs and devices using biomimetic polyphosphate technology to control bleeding and accelerate healing.

Pregenerate, Inc., founded in 2019 and incorporated in Delaware, specializes in developing innovative organ-on-a-chip technology aimed at replacing animal testing in medical and pharmaceutical research, particularly for arthritis treatments. The company's scalable models utilize human cells, allowing pharmaceutical companies to significantly reduce costs and improve drug success rates. Pregenerate's technology not only enhances the efficiency of research but also facilitates the stratification of patients into targeted treatment subgroups, enabling personalized medicine approaches. By providing these advanced solutions, Pregenerate aims to transform the research landscape and improve treatment outcomes for individuals with arthritis.